BMS 986094
Alternative Names: BMS-986094; HCV NS5b polymerase inhibitors - Inhibitex; HCV polymerase inhibitors - Inhibitex; INX-08189; INX-189Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Cardiff University; Katholieke Universiteit Leuven; University of Georgia
- Developer Inhibitex
- Class Antivirals; Naphthalenes; Nucleosides; Purine nucleotides; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 30 Apr 2013 Duke University initiates a longitudinal study evaluating the incidence of cardiac and renal dysfunction in patients exposed to BMS 986094 in USA (NCT01846494)
- 23 Aug 2012 Discontinued - Phase-I/II for Hepatitis C in Puerto Rico (PO)
- 23 Aug 2012 Discontinued - Phase-II for Hepatitis C in USA (PO)